build-out continues:
James O'Shea Former Zeneca Executive Joins Sepracor As President
James O'Shea Former Zeneca Executive Joins Sepracor As President and Chief Operating Officer
MARBOROUGH, Mass., Sept. 20 /PRNewswire/ -- Sepracor Inc. (Nasdaq: SEPR) today announced the appointment of James O'Shea to the newly created position of President and Chief Operating Officer. Mr. O'Shea was previously Senior Vice President of Sales, Marketing and Medical Affairs for Zeneca, Inc., the $2.2 billion U.S. unit of the former Zeneca Group plc, which merged with Astra AB in 1999 to form AstraZeneca plc. At Zeneca, Mr. O'Shea was responsible for all commercial and medical operations of the U.S. subsidiary.
"We are pleased to have Jim as a key member of the Sepracor management team," said Timothy J. Barberich, Chief Executive Officer of Sepracor. "Jim brings with him a depth of experience in building and leading effective commercial organizations."
Throughout his 23 years of global pharmaceutical management experience, Mr. O'Shea was instrumental in growing Zeneca's U.S. business to over $2 billion in revenues. Over the past several years he led the launch of ten successful pharmaceutical products, which are leaders in a number of
therapeutic categories, including respiratory therapy, central nervous system disorders, women's health, and oncology.
"I am excited about the prospect of Sepracor becoming a major player as a fully integrated pharmaceutical company. The Company's chemistry-based approach for discovery of both improved and new chemical entities, has produced a robust near-term pipeline which can lead to a very large pharmaceutical business," said James O'Shea. |
